SEC Form 4 · accession 0001179110-17-000203
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin F McLaughlin
Officer — SVP, CFO and Treasurer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 3, 2017 | M | 10,000 | $3.88 | A | 72,600 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $3.88 | Jan 3, 2017 | M | 10,000 | D | — | Dec 2, 2020 | Common Stock | 10,000 | 6,251 | D |
Explanation of responses
- F1The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.